نتایج جستجو برای: mrd

تعداد نتایج: 1567  

Journal: :Blood 2014
Valentino Conter Maria Grazia Valsecchi Rosanna Parasole Maria Caterina Putti Franco Locatelli Elena Barisone Luca Lo Nigro Nicola Santoro Maurizio Aricò Ottavio Ziino Andrea Pession Anna Maria Testi Concetta Micalizzi Fiorina Casale Marco Zecca Gabriella Casazza Paolo Tamaro Gaetano La Barba Lucia Dora Notarangelo Daniela Silvestri Antonella Colombini Carmelo Rizzari Andrea Biondi Giuseppe Masera Giuseppe Basso

The outcome of high-risk (HR) acute lymphoblastic leukemia patients enrolled in the AIEOP-BFM ALL 2000 study in Italy is described. HR criteria were minimal residual disease (MRD) levels ≥10(-3) at day 78 (MRD-HR), no complete remission (CR) at day 33, t(4;11) translocation, and prednisone poor response (PPR). Treatment (2 years) included protocol I, 3 polychemotherapy blocks, delayed intensifi...

Journal: :Blood 2015
Michaela Kotrova Katerina Muzikova Ester Mejstrikova Michaela Novakova Violeta Bakardjieva-Mihaylova Karel Fiser Jan Stuchly Mathieu Giraud Mikaël Salson Christiane Pott Monika Brüggemann Marc Füllgrabe Jan Stary Jan Trka Eva Fronkova

The predictive strength of next-generation sequencing MRD detection for relapse compared with current methods in childhood ALL Minimal residual disease (MRD) monitoring via antigen receptor quantitative polymerase chain reaction (qPCR) is an important pre-dictor of outcome in childhood acute lymphoblastic leukemia (ALL), is rigorously standardized within the EuroMRD consortium and has a greater...

Journal: :Biology of Blood and Marrow Transplantation 2014

Journal: :Haematologica 2017
Nicola Gökbuget Gerhard Zugmaier Matthias Klinger Peter Kufer Matthias Stelljes Andreas Viardot Heinz A Horst Svenja Neumann Monika Brüggemann Oliver G Ottmann Thomas Burmeister Dorothea Wessiepe Max S Topp Ralf Bargou

In adults with acute lymphoblastic leukemia (ALL), advances in chemotherapy have improved hematologic response rates to greater than 80% and relapses rates to below 50%. Leukemic cells not detected by conventional morphological methods may persist or reappear after chemotherapy as minimal residual disease (MRD), defined as at least 10 (0.01%) leukemic cells detected by quantitative polymerase c...

2017
Hiroyuki Takamatsu

Multiple myeloma (MM) is a hematological malignancy with a poor prognosis, characterized by clonal proliferation of plasma cells in the bone marrow (BM). Relapse due to undetected minimal residual disease (MRD) is the leading cause of death among patients with MM. This review summarizes the methods and prognostic value of MRD assessment in BM and autografts from MM patients who underwent autolo...

Journal: :CoRR 2017
Rocco Trombetti Yue Zhou

In this paper, we present a new family of maximum rank distance (MRD for short) codes in F q of minimum distance 2 ≤ d ≤ 2n. In particular, when d = 2n, we can show that the corresponding semifield is exactly a Hughes-Kleinfeld semifield. The middle and right nuclei of these MRD codes are both equal to Fqn . We also prove that the MRD codes of minimum distance 2 < d < 2n in this family are ineq...

Journal: :Blood 2013
Wael Saber Corey S Cutler Ryotaro Nakamura Mei-Jie Zhang Ehab Atallah J Douglas Rizzo Richard T Maziarz Jorge Cortes Matt E Kalaycio Mary M Horowitz

Allogeneic hematopoietic cell transplantation (HCT) from human leukocyte antigen (HLA) matched related donor (MRD) and matched unrelated donors (MUD) produces similar survival for patients with acute myelogenous leukemia. Whether these results can be extended to patients with myelodysplastic syndromes (MDS) is unknown. Therefore, analysis of post-HCT outcomes for MDS was performed. Outcomes of ...

2013
N Feller V H J van der Velden R A Brooimans N Boeckx F Preijers A Kelder I de Greef G Westra J G te Marvelde P Aerts H Wind M Leenders J W Gratama G J Schuurhuis

Flow-cytometric detection of minimal residual disease (MRD) has proven in several single-institute studies to have an independent prognostic impact. We studied whether this relatively complex approach could be performed in a multicenter clinical setting. Five centers developed common protocols to accurately define leukemia-associated (immuno)phenotypes (LAPs) at diagnosis required to establish ...

Journal: :The Journal of allergy and clinical immunology 2012
Caridad A Martinez Sweta Shah William T Shearer Howard M Rosenblatt Mary E Paul Javier Chinen Kathryn S Leung Alana Kennedy-Nasser Malcolm K Brenner Helen E Heslop Hao Liu Meng-Fen Wu Imelda C Hanson Robert A Krance

BACKGROUND Matched related donor (MRD) hematopoietic stem cell transplantation (HSCT) is a successful treatment for chronic granulomatous disease (CGD), but the safety and efficacy of HSCT from unrelated donors is less certain. OBJECTIVE We evaluated the outcomes and overall survival in patients with CGD after HSCT. METHODS We report the outcomes for 11 children undergoing HSCT from an MRD ...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2012
Janine Stutterheim Fatima Ait Ichou Emmy den Ouden Rogier Versteeg Huib N Caron Godelieve A M Tytgat C Ellen van der Schoot

PURPOSE PCR-based detection of minimal residual disease (MRD) in neuroblastoma (NB) is presently based on NB-specific transcripts. However, the expression of these targets varies between patients and upon treatment, and only PHOX2B is truly specific. RASSF1a is methylated (RASSF1a(M)) in NB, and we investigated whether it can serve as a specific and stable DNA MRD marker. PATIENTS AND METHODS...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید